The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study
Open accessAbstract
Background To date, few data on paediatric COVID-19 have been published, and most reports originate from China. This study aimed to capture key data on children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection across Europe to inform physicians and health-care service planning during the ongoing pandemic. Methods This multicentre cohort study involved 82 participating health-care institutions across 25 European countries, using a well established research network—the Paediatric Tuberculosis Network European Trials Group (ptbnet)—that mainly comprises paediatric infectious diseases specialists and paediatric pulmonologists. We included all individuals aged 18 years or younger with confirmed SARS-CoV-2 infection, detected at any anatomical site by RT-PCR, between April 1 and April 24, 2020, during the initial peak of the European COVID-19 pandemic. We explored factors associated with need for intensive care unit (ICU) admission and initiation of drug treatment for COVID-19 using univariable analysis, and applied multivariable logistic regression with backwards stepwise analysis to further explore those factors significantly associated with ICU admission. Findings 582 individuals with PCR-confirmed SARS-CoV-2 infection were included, with a median age of 5·0 years (IQR 0·5–12·0) and a sex ratio of 1·15 males per female. 145 (25%) had pre-existing medical conditions. 363 (62%) individuals were admitted to hospital. 48 (8%) individuals required ICU admission, 25 (4%) mechanical ventilation (median duration 7 days, IQR 2–11, range 1–34), 19 (3%) inotropic support, and one (<1%) extracorporeal membrane oxygenation. Significant risk factors for requiring ICU admission in multivariable analyses were being younger than 1 month (odds ratio 5·06, 95% CI 1·72–14·87; p=0·0035), male sex (2·12, 1·06–4·21; p=0·033), pre-existing medical conditions (3·27, 1·67–6·42; p=0·0015), and presence of lower respiratory tract infection signs or symptoms at presentation (10·46, 5·16–21·23; p<0·0001). The most frequently used drug with antiviral activity was hydroxychloroquine (40 [7%] patients), followed by remdesivir (17 [3%] patients), lopinavir–ritonavir (six [1%] patients), and oseltamivir (three [1%] patients). Immunomodulatory medication used included corticosteroids (22 [4%] patients), intravenous immunoglobulin (seven [1%] patients), tocilizumab (four [1%] patients), anakinra (three [1%] patients), and siltuximab (one [<1%] patient). Four children died (case-fatality rate 0·69%, 95% CI 0·20–1·82); at study end, the remaining 578 were alive and only 25 (4%) were still symptomatic or requiring respiratory support. Interpretation COVID-19 is generally a mild disease in children, including infants. However, a small proportion develop severe disease requiring ICU admission and prolonged ventilation, although fatal outcome is overall rare. The data also reflect the current uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed. Funding ptbnet is supported by Deutsche Gesellschaft für Internationale Zusammenarbeit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spread of SARS-CoV-2 in the Icelandic population
Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006100 · Cited by 1,248
Castagnoli, R., Votto, M., Licari, A., Brambilla, I., Bruno, R., Perlini, S., Rovida, F., Baldanti, F., & Marseglia, G. L. (2020) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2020.1467 · Cited by 1,085
Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny
Kollmann, T. R., Kampmann, B., Mazmanian, S. K., Marchant, A., & Levy, O. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.009 · Cited by 478
Cited by
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
COVID-19 and multisystem inflammatory syndrome in children and adolescents
Jiang, L., Tang, K., Levin, M., Irfan, O., Morris, S. K., Wilson, K., Klein, J. D., & Bhutta, Z. A. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30651-4 · Cited by 826
Feldstein, L. R., Tenforde, M. W., Friedman, K. G., Newhams, M., Rose, E. B., Dapul, H., Soma, V. L., Maddux, A. B., Mourani, P. M., Bowens, C., et al. (2021) · JAMA · doi:10.1001/jama.2021.2091 · Cited by 817
Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
Zhang, J.-J., Dong, X., Liu, G.-H., & Gao, Y.-D. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08921-5 · Cited by 715
Piroth, L., Cottenet, J., Mariet, A.-S., Bonniaud, P., Blot, M., Tubert-Bitter, P., & Quantin, C. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30527-0 · Cited by 600
Metadata
- Authors
- Götzinger, F., Santiago-García, B., Noguera-Julián, A., Lanaspa, M., Lancella, L., Calò Carducci, F. I., Gabrovska, N., Velizarova, S., Prunk, P., Osterman, V., Krivec, U., Lo Vecchio, A., Shingadia, D., Soriano-Arandes, A., Melendo, S., Lanari, M., Pierantoni, L., Wagner, N., L'Huillier, A. G., Heininger, U., Ritz, N., Bandi, S., Krajcar, N., Roglić, S., Santos, M., Christiaens, C., Creuven, M., Buonsenso, D., Welch, S. B., Bogyi, M., Brinkmann, F., Tebruegge, M., Pfefferle, J., Zacharasiewicz, A., Berger, A., Berger, R., Strenger, V., Kohlfürst, D. S., Zschocke, A., Bernar, B., Simma, B., Haberlandt, E., Thir, C., Biebl, A., Vanden Driessche, K., Boiy, T., Van Brusselen, D., Bael, A., Debulpaep, S., Schelstraete, P., Pavic, I., Nygaard, U., Glenthoej, J. P., Heilmann Jensen, L., Lind, I., Tistsenko, M., Uustalu, Ü., Buchtala, L., Thee, S., Kobbe, R., Rau, C., Schwerk, N., Barker, M., Tsolia, M., Eleftheriou, I., Gavin, P., Kozdoba, O., Zsigmond, B., Valentini, P., Ivaškeviciene, I., Ivaškevicius, R., Vilc, V., Schölvinck, E., Rojahn, A., Smyrnaios, A., Klingenberg, C., Carvalho, I., Ribeiro, A., Starshinova, A., Solovic, I., Falcón, L., Neth, O., Minguell, L., Bustillo, M., Gutiérrez-Sánchez, A. M., Guarch Ibáñez, B., Ripoll, F., Soto, B., Kötz, K., Zimmermann, P., Schmid, H., Zucol, F., Niederer, A., Buettcher, M., Cetin, B. S., Bilogortseva, O., Chechenyeva, V., Demirjian, A., Shackley, F., McFetridge, L., Speirs, L., Doherty, C., Jones, L., McMaster, P., Murray, C., Child, F., Beuvink, Y., Makwana, N., Whittaker, E., Williams, A., Fidler, K., Bernatoniene, J., Song, R., Oliver, Z., & Riordan, A.
- Venue
- The Lancet Child & Adolescent Health
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 4
- Issue
- 9
- Pages
- 653-661
- ISSN
- 2352-4642 (ISSN-L)
- OpenAlex
- W3037183278
- Cited by
- 1,219
- References
- 3
- FWCI
- 31.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. https://app.cochat.ai/papers/10.1016/s2352-4642(20)30177-2
- The paper
- Götzinger, F., Santiago-García, B., Noguera-Julián, A., Lanaspa, M., Lancella, L., Calò Carducci, F. I., Gabrovska, N., Velizarova, S., Prunk, P., Osterman, V., Krivec, U., Lo Vecchio, A., Shingadia, D., Soriano-Arandes, A., Melendo, S., Lanari, M., Pierantoni, L., Wagner, N., L'Huillier, A. G., . . . Riordan, A. (2020). COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child & Adolescent Health. https://doi.org/10.1016/s2352-4642(20)30177-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.